361 related articles for article (PubMed ID: 25045997)
41. Preparation and evaluation of orally disintegrating tablets containing vitamin E as a model fat-soluble drug.
Ikematsu Y; Uchida S; Namiki N
Chem Pharm Bull (Tokyo); 2015; 63(3):156-63. PubMed ID: 25757486
[TBL] [Abstract][Full Text] [Related]
42. Formulation and optimization of orally disintegrating tablets of sumatriptan succinate.
Sheshala R; Khan N; Darwis Y
Chem Pharm Bull (Tokyo); 2011; 59(8):920-8. PubMed ID: 21804234
[TBL] [Abstract][Full Text] [Related]
43. [Clinical functionality required for orally disintegrating tablets selected as the next generation type].
Namiki N
Yakugaku Zasshi; 2015; 135(2):237-43. PubMed ID: 25747219
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo investigation of taste-masking effectiveness of Eudragit E PO as drug particle coating agent in orally disintegrating tablets.
Drašković M; Medarević D; Aleksić I; Parojčić J
Drug Dev Ind Pharm; 2017 May; 43(5):723-731. PubMed ID: 27494420
[TBL] [Abstract][Full Text] [Related]
45. Formulation and in vitro evaluation of ketoprofen fast-dissolving tablets.
Comoglu T; Inal O; Yaacoub HB
Pharm Dev Technol; 2016 Dec; 21(8):901-908. PubMed ID: 25798913
[TBL] [Abstract][Full Text] [Related]
46. A new formulation for orally disintegrating tablets using a suspension spray-coating method.
Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
Int J Pharm; 2009 Dec; 382(1-2):80-7. PubMed ID: 19686825
[TBL] [Abstract][Full Text] [Related]
47. Clinical disintegration time of orally disintegrating tablets clinically available in Japan in healthy volunteers.
Yoshita T; Uchida S; Namiki N
Biol Pharm Bull; 2013; 36(9):1488-93. PubMed ID: 23995661
[TBL] [Abstract][Full Text] [Related]
48. Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets.
Loke YH; Chew YL; Janakiraman AK; Lee SK; Uddin ABMH; Goh CF; Kee PE; Ng HS; Ming LC; Liew KB
Drug Dev Ind Pharm; 2024 Jan; 50(1):36-44. PubMed ID: 38149637
[TBL] [Abstract][Full Text] [Related]
49. Effect of granule properties on rough mouth feel and palatability of orally disintegrating tablets.
Kimura S; Uchida S; Kanada K; Namiki N
Int J Pharm; 2015 Apr; 484(1-2):156-62. PubMed ID: 25681720
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus.
Brniak W; Jachowicz R; Krupa A; Skorka T; Niwinski K
Pharm Dev Technol; 2013; 18(2):464-74. PubMed ID: 22881600
[TBL] [Abstract][Full Text] [Related]
51. Formulation of multiparticulate systems as lyophilised orally disintegrating tablets.
Alhusban F; Perrie Y; Mohammed AR
Eur J Pharm Biopharm; 2011 Nov; 79(3):627-34. PubMed ID: 21693189
[TBL] [Abstract][Full Text] [Related]
52. New perspective to develop memantine orally disintegrating tablet formulations: SeDeM expert system.
Gülbağ S; Yılmaz Usta D; Gültekin HE; Oktay AN; Demirtaş Ö; Karaküçük A; Çelebi N
Pharm Dev Technol; 2018 Jun; 23(5):512-519. PubMed ID: 28657404
[TBL] [Abstract][Full Text] [Related]
53. New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook.
Elwerfalli AM; Ghanchi Z; Rashid F; Alany RG; ElShaer A
Curr Drug Deliv; 2015; 12(6):652-67. PubMed ID: 25760951
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics.
Lou H; Liu M; Qu W; Hu Z; Brunson E; Johnson J; Almoazen H
Drug Dev Ind Pharm; 2014 Jul; 40(7):910-8. PubMed ID: 23621768
[TBL] [Abstract][Full Text] [Related]
55. Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression.
Olmez SS; Vural I; Sahin S; Ertugrul A; Capan Y
Pharmazie; 2013 Feb; 68(2):110-6. PubMed ID: 23469682
[TBL] [Abstract][Full Text] [Related]
56. Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability.
Takano H; Uchida S; Kashiwagura Y; Tanaka S; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
Chem Pharm Bull (Tokyo); 2019; 67(2):112-119. PubMed ID: 30713270
[TBL] [Abstract][Full Text] [Related]
57. Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression.
Gulsun T; Ozturk N; Kaynak MS; Vural I; Sahin S
Pharmazie; 2017 Jul; 72(7):389-394. PubMed ID: 29441935
[TBL] [Abstract][Full Text] [Related]
58. Application of Texture Analysis Technique in Formulation Development of Lyophilized Orally Disintegrating Tablets Containing Mannitol, Polyvinylpyrrolidone and Amino Acids.
Hackl E; Ermolina I
AAPS PharmSciTech; 2019 Jan; 20(2):71. PubMed ID: 30631978
[TBL] [Abstract][Full Text] [Related]
59. Bitterness evaluation of intact and crushed Vesicare orally disintegrating tablets using taste sensors.
Haraguchi T; Miyazaki A; Yoshida M; Uchida T
J Pharm Pharmacol; 2013 Jul; 65(7):980-7. PubMed ID: 23738725
[TBL] [Abstract][Full Text] [Related]
60. Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets.
Tayel SA; El Nabarawi MA; Amin MM; AbouGhaly MH
AAPS PharmSciTech; 2017 Feb; 18(2):410-423. PubMed ID: 27038484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
